Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives $8.25 Consensus PT from Brokerages

Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) have received a consensus rating of “Buy” from the four ratings firms that are presently covering the company, Marketbeat Ratings reports. Four research analysts have rated the stock with a buy rating. The average 12-month target price among brokerages that have covered the stock in the last year is $8.25.

A number of research analysts recently issued reports on AMRX shares. The Goldman Sachs Group lifted their price target on shares of Amneal Pharmaceuticals from $6.25 to $8.00 and gave the company a “buy” rating in a research report on Monday, May 6th. Truist Financial reiterated a “buy” rating and set a $9.00 target price (up from $7.00) on shares of Amneal Pharmaceuticals in a report on Monday, May 6th. Piper Sandler upped their price target on Amneal Pharmaceuticals from $6.00 to $8.00 and gave the stock an “overweight” rating in a research note on Thursday, March 21st. Finally, StockNews.com downgraded Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, March 4th.

Amneal Pharmaceuticals Trading Down 0.8 %

AMRX opened at $6.42 on Friday. The company has a quick ratio of 0.97, a current ratio of 1.65 and a debt-to-equity ratio of 121.31. Amneal Pharmaceuticals has a 52 week low of $2.29 and a 52 week high of $7.25. The stock has a market cap of $1.98 billion, a PE ratio of -11.46 and a beta of 1.19. The business has a 50 day moving average of $6.51 and a 200-day moving average of $5.94.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its quarterly earnings data on Friday, May 3rd. The company reported $0.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.08 by $0.04. Amneal Pharmaceuticals had a positive return on equity of 234.06% and a negative net margin of 6.76%. The business had revenue of $659.19 million during the quarter, compared to the consensus estimate of $623.08 million. Equities research analysts predict that Amneal Pharmaceuticals will post 0.51 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Amneal Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the company. Gladius Capital Management LP purchased a new stake in Amneal Pharmaceuticals during the 3rd quarter valued at $39,000. Sherbrooke Park Advisers LLC purchased a new stake in shares of Amneal Pharmaceuticals during the third quarter valued at $54,000. Atlanta Consulting Group Advisors LLC purchased a new stake in shares of Amneal Pharmaceuticals during the first quarter valued at $61,000. Trexquant Investment LP bought a new stake in Amneal Pharmaceuticals in the 4th quarter worth about $65,000. Finally, Bayesian Capital Management LP purchased a new position in Amneal Pharmaceuticals in the 1st quarter worth about $65,000. 31.82% of the stock is currently owned by hedge funds and other institutional investors.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.